Literature DB >> 1233243

On the pharmacokinetics of proscillaridin A in man.

K E Andersson, A Bertler, A Redfors.   

Abstract

The plasma concentration of proscillaridin was measured by a modified 86Rb method during treatment with multiple doses of a commercial preparation of proscillaridin. Despite high doses, very low plasma levels were found, and there were only minute amounts of glycoside activity in urine and faeces. Administration of an enteric-coated proscillaridin preparation gave higher plasma levels, which raises the possibility of inactivation of the glycoside by acid gastric juice. The results suggest that proscillaridin has low biological availability when given orally, and that it is extensively metabolised in the body.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1233243     DOI: 10.1007/bf00562316

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  Studies with tritiated digoxin in human subjects after intravenous administration.

Authors:  J E DOHERTY; W H PERKINS
Journal:  Am Heart J       Date:  1962-04       Impact factor: 4.749

2.  In vitro stability of proscillaridin A.

Authors:  K E Andersson; A Bertler; A Redfors
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

3.  Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay.

Authors:  T W Smith; V P Butler; E Haber
Journal:  N Engl J Med       Date:  1969-11-27       Impact factor: 91.245

4.  [Clinical experimental studies with the heart glycoside, proscillaridin, with special reference to its enteral resorption rate].

Authors:  G G Belz
Journal:  Med Klin       Date:  1968-01-19

5.  An improved method of estimating digoxin in human plasma.

Authors:  A Bertler; A Redfors
Journal:  Clin Pharmacol Ther       Date:  1970 Sep-Oct       Impact factor: 6.875

6.  [Contribution to the quantitative and qual-itative study on the glycoside proscillaridin].

Authors:  D Wülfing von der Heyden
Journal:  Med Welt       Date:  1969-03-29

7.  [Therapeutic experiences with a new cardiac glycoside: proscillaridin A].

Authors:  G Meier; G Wagner
Journal:  Med Welt       Date:  1965-08-28

8.  [Therapeutic examination of proscillaridin A].

Authors:  K H Butzengeiger; U Graeber; J Lange; R Schumacher
Journal:  Dtsch Med Wochenschr       Date:  1967-12-01       Impact factor: 0.628

9.  [Clinical-experimental study on the characterization of a cardiac glycoside].

Authors:  J Hänel; G Meiffert
Journal:  Med Welt       Date:  1966-06-25

10.  [Clinical studies with a new cardiac glycoside proscillaridine A (Sandoscill)].

Authors:  J Hansel
Journal:  Med Klin       Date:  1968-06-07
View more
  3 in total

1.  Proscillaridin activity in portal and peripheral venous blood after oral administration to man.

Authors:  K E Andersson; B Bergdahl; H Dencker; G Wettrell
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

2.  Biliary excretion and enterochepatic recycling of proscillaridin A after oral adminstration to man.

Authors:  K E Andersson; B Bergdahl; G Wettrell
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

3.  Stability in vitro of methylproscillaridin.

Authors:  B Bergdahl; K E Andersson
Journal:  Eur J Clin Pharmacol       Date:  1977-04-20       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.